 |
| JP Nadda |
New Delhi, December 26, 2025:
Union Minister for Health and Family Welfare, Shri Jagat Prakash Nadda, today reviewed the progress, achievements, and future initiatives of the Indian Pharmacopoeia Commission (IPC), reaffirming the Government of India’s commitment to strengthening medicine quality, patient safety, and global healthcare standards.
The review meeting was held in the presence of Ms. Nivedita Shukla Verma, Secretary, Department of Chemicals and Petro-Chemicals (DoCP), who is also holding additional charge as Secretary, Ministry of Health and Family Welfare (MoHFW), along with senior officials of the ministry.
Strengthening Standards for a Self-Reliant India
During the meeting, Shri Nadda commended IPC’s sustained efforts in strengthening pharmacopoeial standards and pharmacovigilance systems. He noted that these initiatives play a crucial role in advancing the Government’s vision of Atmanirbhar Bharat and Viksit Bharat, built on self-reliance, scientific excellence, and strong healthcare regulation.
The Minister highlighted IPC’s pivotal responsibility in ensuring the quality, safety, and efficacy of medicines, emphasizing that the Indian Pharmacopoeia continues to serve as a critical scientific and regulatory reference that maintains uniform drug standards across the country.
 |
| J P Nadda Reviews Progress of Indian Pharmacopoeia Commission |
Indian Pharmacopoeia Gains Global Recognition
A key highlight of the review was the growing international acceptance of Indian pharmacopoeial standards. Shri Nadda stated that:
“The Indian Pharmacopoeia is now recognised in 19 countries, reflecting increasing global confidence in India’s regulatory and scientific capabilities.”
He further observed that this recognition strengthens India’s position as the ‘Pharmacy of the World’ and reinforces the credibility of Indian medicine standards on the global stage.
Indian Pharmacopoeia 2026 to Be Launched Soon
The Union Health Minister also announced that the 10th edition of the Indian Pharmacopoeia 2026 will be formally launched in the first week of January 2026. The new edition is expected to further enhance scientific rigor, regulatory clarity, and alignment with international standards.
Focus on Patient Safety and Pharmacovigilance
Shri Nadda emphasized IPC’s critical role in implementing the Pharmacovigilance Programme of India (PvPI), which monitors adverse drug reactions to ensure patient safety. He appreciated IPC’s efforts to strengthen reporting mechanisms and build capacity among healthcare professionals across the country.
The Minister also encouraged IPC to continue focusing on innovation, digitalisation, and global harmonisation of standards, in line with the long-term vision of Viksit Bharat, to ensure universal access to safe and quality medicines.
IPC Reaffirms Commitment to National and Global Health
Presenting the details of IPC’s ongoing and future activities, Dr. V. Kalaiselvan, Secretary-cum-Scientific Director of IPC, reaffirmed the Commission’s commitment to further strengthening pharmacopoeial and pharmacovigilance standards. He also highlighted IPC’s focus on expanding international collaboration while contributing to both national and global public health goals.
Senior officials, including Shri Harsh Mangla, Joint Secretary, MoHFW, and other officers of the Ministry, were also present during the review meeting.
Source: PIB Delhi
Posted on: December 26, 2025
More:
1. Polio: Why Your Child Still Needs Those Two Drops!